Location Directory

Clinical trials in Chicago, Illinois

This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

17832

Shown on this page

Current sort

Institutions in Chicago

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic), Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Liver Cancer Stage IV, Liver Cancer Stage IIIa, Liver Cancer Stage IIIb, Liver Cancer Stage IIIc
Interventions: EUS-Guided MWA Device; Device
Lead sponsor: Banner Health; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Gilbert, Arizona • Los Angeles, California • Chicago, Illinois + 3 more

Conditions: Localized Prostate Cancer
Interventions: Aquablation Therapy, Active Surveillance; Device · Other
Lead sponsor: PROCEPT BioRobotics; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 27
States / cities: Chandler, Arizona • Los Angeles, California • Murrieta, California + 23 more

Conditions: Coronavirus Disease (COVID-19)
Interventions: Molnupiravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,082 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 71
States / cities: Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more

Conditions: Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Interventions: Valemetostat Tosylate; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 10 more

Conditions: Carcinoma, Renal Cell
Interventions: Belzutifan, Lenvatinib, Cabozantinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 33
States / cities: Chandler, Arizona • Los Angeles, California • Orange, California + 27 more

Conditions: Proliferative Sickle Cell Retinopathy
Interventions: Faricimab Injection for stage 3 or stage 4 Proliferative sickle cell eyes, Vitrectomy, Laser photocoagulation; Drug · Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypogonadism, Male
Interventions: Testosterone enanthate; Combination Product
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 12 Years to 17 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 22
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 18 more

Conditions: Wrinkle, Lax Skin, Lines Skin
Interventions: Thermage FLX; Device
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 30 Years to 60 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Sacramento, California • San Diego, California • Chicago, Illinois + 3 more

Conditions: Alzheimer's Disease
Interventions: Trontinemab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 24
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 20 more

Conditions: Prostate Cancer
Interventions: Enzalutamide, LY2157299; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland

Conditions: Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Interventions: Tarlatamab, Durvalumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 37
States / cities: Mobile, Alabama • Los Angeles, California • New Haven, Connecticut + 32 more

Conditions: Paroxysmal AF
Interventions: Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System; Device
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 24
States / cities: Jonesboro, Arkansas • La Jolla, California • Sacramento, California + 19 more

Clinical trials in Chicago, Illinois

Filter and sort this location

Institutions in Chicago

Live official records

CREO - Microwave Ablation Feasibility Study

WATER IV PCa (AS Sub-study)

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS)

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)